论文部分内容阅读
心力衰竭(heart failure, HF)是常见的心血管疾病,3年病死率约为60%。因心力衰竭住院的患者在以后12周内因心力衰竭再住院或死亡的发生率为25%。心力衰竭所致的死亡率在我国呈逐年上升趋势,在较短时间内对心力衰竭患者作出正确的诊断十分重要。传统诊断心衰的指标主要依靠心电图、超声心动图和临床体征,一直缺乏有效评价心脏功能的实验室检测指标,生物标志物分析可能是心衰诊断的重要补充。目前几个大的、以成果为基础的研究,正着手调查使用BNP系列监测心衰病人的发病率,死亡率及整体医疗费用的降低。1N末端前脑钠肽原1. 1 BNP与NT-proBNP的生物学特性
Heart failure (HF) is a common cardiovascular disease with a 3-year case-fatality rate of about 60%. Patients hospitalized with heart failure had a 25% incidence of further hospitalizations or deaths due to heart failure within the next 12 weeks. The mortality rate due to heart failure is on the rise in China. It is very important to make the correct diagnosis of heart failure patients in a relatively short period of time. Traditional indicators of heart failure mainly rely on ECG, echocardiography and clinical signs. There is a lack of laboratory tests that can effectively evaluate cardiac function. Biomarker analysis may be an important complement to heart failure diagnosis. Several large, outcome-based studies are currently investigating the use of the BNP series to monitor the morbidity, mortality and overall medical costs of people with heart failure. 1 N-terminal pro-brain natriuretic peptide 1.1 biological characteristics of BNP and NT-proBNP